A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Bibliographic Details
Main Authors:	S. Ward, E. Morris, N. Bansback, N. Calvert, A. Crellin, D. Forman, M. Larvin, D. Radstone
Format:	Article
Language:	English
Published:	NIHR Journals Library 2001-01-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta5240

Similar Items

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer
by: A. Clegg, et al.
Published: (2001-01-01)

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
by: Lloyd Jones, et al.
Published: (2001-01-01)

The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation
by: A Takeda, et al.
Published: (2007-05-01)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
by: Gustav J Ullenhag, et al.
Published: (2017-01-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

Mechanisms of gemcitabine resistance in pancreatic cancer
by: Melling, J.
Published: (2017)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
by: Guo ZY, et al.
Published: (2018-08-01)

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
by: Zu-Yao Yang, et al.
Published: (2013-01-01)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
by: Elena Gabriela Chiorean, et al.
Published: (2019-05-01)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01)

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity
by: S. O'Meara, et al.
Published: (2001-01-01)

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer
by: C. Forbes, et al.
Published: (2001-01-01)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
by: Narayan Rajan, et al.
Published: (2014-12-01)

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
by: Victor H. F. de Jesus, et al.
Published: (2020-02-01)

Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
Published: (2019-08-01)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
by: Amber Blaauboer, et al.
Published: (2020-09-01)

Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
by: James J Lee, et al.
Published: (2013-01-01)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
by: Habermehl Daniel, et al.
Published: (2012-03-01)

Role of ABCC5 in Gemcitabine Resistance in Pancreatic Cancer
by: Bugde, Piyush
Published: (2019)

BI 6727 and gemcitabine combination therapy in pancreatic cancer
by: Jones, O. P.
Published: (2018)

Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer
by: Qin, Li
Published: (2015)

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
by: Leblond Lorraine, et al.
Published: (2007-07-01)

Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis
by: ZI Li
Published: (2020-01-01)

Clinical effect of nanoparticle albumin-bound paclitaxel combined with gemcitabine in treatment of advanced pancreatic cancer: A meta-analysis
by: WANG Yun, et al.
Published: (2019-05-01)

Therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer
by: JI Hongbing, et al.
Published: (2016-03-01)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
by: Xin Miao, et al.
Published: (2016-11-01)

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
by: J. Bryant, et al.
Published: (2001-01-01)

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
by: Venkatasubbaiah A. Venkatesha, et al.
Published: (2012-06-01)

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review
by: A. Stewart, et al.
Published: (2001-01-01)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
by: Yunjiang Zhou, et al.
Published: (2019-04-01)

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
by: Wang Y, et al.
Published: (2016-06-01)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
by: Moehler Markus, et al.
Published: (2011-08-01)

Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
by: Myoungjae Kim, et al.
Published: (2019-10-01)

Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties
by: Sungwoo Hong, et al.
Published: (2018-10-01)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
by: Wu LW, et al.
Published: (2019-06-01)

The role of osteopontin-mediated autophagy in gemcitabine resistance of pancreatic cancer
by: Yu-TingHuang, et al.
Published: (2017)

Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells
by: Fadina Kuryayeva, et al.
Published: (2019-12-01)

Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer
by: A. Rajabpour, et al.
Published: (2017-10-01)